Alembic Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹937.80(-0.30%)June 23, 2025 15:29:39 PM IST
- NSE
- BSE
- Vol : 143.09K (NSE + BSE)Last 20 day avg : 93.23 K
Alembic Pharmaceuticals is trading -0.30% lower at Rs 937.80 as compared to its last closing price. Alembic Pharmaceuticals has been trading in the price range of 946.55 & 923.15. Alembic Pharmaceuticals has given -12.34% in this year & -6.45% in the last 5 days. Alembic Pharmaceuticals has TTM P/E ratio 31.32 as compared to the sector P/E of 22.54.There are 11 analysts who have initiated coverage on Alembic Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 156.87 Crores in its last quarter.Listed peers of Alembic Pharmaceuticals include Syngene International (0.65%), Eris Lifesciences (-0.25%), Alembic Pharmaceuticals (-0.30%).The Mutual Fund holding in Alembic Pharmaceuticals was at 9.20% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Alembic Pharmaceuticals was at 3.94% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 23, 2025, 10:45 AM UTC
- Dividend YieldHigher than industry1.18Annual dividends as a percentage of the stock price.
- P/BIn line with historical values3.54The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values31.48Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.71Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.24The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 16.65% from Rs 1769.63 crore to Rs 1516.98 crore, year-on-year
The company's profit declined by 11.97% year-on-year during the March quarter, dropping from Rs 178.21 crore to Rs 156.87 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,063.87
- R2
- 1,110.53
- R3
- 1,180.82
- S1
- 946.92
- S2
- 876.63
- S3
- 829.97
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Syngene International | Bearish | 636.05 | 0.65 | 25,698.67 | 53.76 | 5.36 | 0.20 | 8.65 |
| Eris Lifesciences | Neutral | 1,620.00 | -0.25 | 22,129.64 | 63.02 | 7.76 | 0.45 | 62.42 |
| Alembic Pharmaceuticals | Neutral | 937.80 | -0.30 | 18,453.49 | 32.22 | 3.54 | 1.18 | 0.90 |
| Jubilant Pharmova | Neutral | 1,123.15 | 1.31 | 17,924.66 | 33.03 | 2.81 | 0.45 | 38.19 |
| Natco Pharma | Bearish | 867.95 | -0.84 | 15,545.84 | 8.31 | 2.06 | 0.69 | 0.06 |
- Promoter(s) holds a high stake in the company at 69.67%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.23 percentage points from previous quarter
- Mutual Funds holding has increased by 0.24 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-06 | Audited Results & Final Dividend |
| 2025-02-03 | Quarterly Results & Others |
| 2024-11-07 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| 2024-05-09 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE901L01018
- BSE Code533573
- NSE CodeAPLLTD
Alembic Pharmaceuticals is trading at 937.80 as on Mon Jun 23 2025 09:59:39. This is -0.30% lower as compared to its previous closing price of 940.65.
The market capitalization of Alembic Pharmaceuticals is 18453.49 Cr as on Mon Jun 23 2025 09:59:39.
The average broker rating on Alembic Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 5 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Alembic Pharmaceuticals is 1296.15 whereas the 52 wk low is 725.60
Alembic Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 31.32
- Sector P/E: 22.54
- Dividend Yield: 1.18%
- D/E ratio: 0.24
Alembic Pharmaceuticals reported a net profit of 583.42 Cr in 2025.
The Mutual Fund Shareholding was 9.20% at the end of 31 Mar 2025.